Analysis of the canine mdr1-1Δ mutation in the dog breed elo

Journal of Veterinary Medicine Series A: Physiology Pathology Clinical Medicine

Volumn 54, Issue 8, 2007, Pages 401-405

  Fecht, S ^a   Wohlke A ^a   Hamann, H ^a   Distl, O ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P;

ALLELE; ANIMAL; ARTICLE; BREEDING; DOG; DOG DISEASE; FEMALE; GENE; GENE DELETION; GENE FREQUENCY; GENETICS; GENOTYPE; MALE; MULTIDRUG RESISTANCE; PHYLOGENY;

ALLELES; ANIMALS; BREEDING; DOG DISEASES; DOGS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE FREQUENCY; GENES, MDR; GENOTYPE; MALE; P-GLYCOPROTEIN; PHYLOGENY; SEQUENCE DELETION;

CANIS FAMILIARIS;

EID: 34548663646     PISSN: 0931184X     EISSN: 14390442     Source Type: Journal    
DOI: 10.1111/j.1439-0442.2007.00966.x     Document Type: Article

References (26)

1. Cordon-Cardo, C., J. P. O'Brien, D. Casals, L. Rittmann-Grauer, J. L. Biedler, M. R. Melamed J. R. Bertino, 1989 : Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl Acad. Sci. USA 86, 695 698.
2. Cordon-Cardo, C., J. P. O'Brien, J. Boccia, D. Casals, J. R. Bertino M. R. Melamed, 1990 : Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38, 1277 1287.
3. Fromm, M. F., 2000 : P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38, 69 74.
4. Fromm, M. F., 2004 : Importance of P-glycoprotein at blood-tissue barriers. Trends. Pharmacol. Sci. 25, 423 429.
5. Geyer, J., B. Döring, J. R. Godoy, R. Leidolf, A. Moritz E. Petzinger, 2005a : Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany. J. Vet. Pharmacol. Ther. 28, 545 551.
6. Geyer, J., B. Döring, J. R. Godoy, A. Moritz E. Petzinger, 2005b : Development of a PCR-based diagnostic test detecting a nt230(del4) MDR1 mutation in dogs: verification in a moxidectin-sensitive Australian Shepherd. J. Vet. Pharmacol. Ther. 28, 95 99.
7. Henik, R. A., H. B. Kellum, S. A. Bentjen K. L. Mealey, 2006 : Digoxin and mexiletine sensitivity in a Collie with the MDR1 mutation. J. Vet. Intern. Med. 20, 415 417.
8. Hugnet, C., S. A. Bentjen K. L. Mealey, 2004 : Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of collies from France. J. Vet. Pharmacol. Ther. 27, 227 229.
9. Kaufhold, J., H. Hamann O. Distl, 2005 : Population genetic analysis of the new dog breed Elo. Berl. Münch. Tierärztl. Wochenschr. 118, 67 75.
10. Kawabata, A., Y. Momoi, M. Inoue-Murayama T. Iwasaki, 2005 : Canine mdr1 gene mutation in Japan. J. Vet. Med. Sci. 67, 1103 1107.
11. Mealey, K. L., S. A. Bentjen, J. M. Gay G. H. Cantor, 2001 : Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11, 727 733.
12. Mealey, K. L., N. C. Northrup S. A. Bentjen, 2003 : Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J. Am. Vet. Med. Assoc. 223, 1453 1455.
13. Mealey, K. L., K. A. Munyard S. A. Bentjen, 2005 : Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of herding breed dogs living in Australia. Vet. Parasitol. 131, 193 196.
14. Mealey, K. L., J. M. Gay, L. G. Martin D. K. Waiting, 2007 : Comparison of the hypothalamic-pituitary-adrenal axis in MDR1-1D and MDR1 wildtype dogs. J. Vet. Emerg. Crit. Care. 17, 61 66
15. Neff, M. W., K. R. Robertson, A. K. Wong, N. Safra, K. W. Broman, M. Slatkin, K. L. Mealey N. C. Pedersen, 2004 : Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc. Natl Acad. Sci. USA 101, 11725 11730.
16. Paul, A. J., W. J. Tranquilli R. L. Seward, 1987 : Clinical observations in Collies given ivermectin orally. Am. J. Vet. Res. 48, 684 685.
17. Preston, J. M., 1983 : Adverse reactions to unapproved applications. Vet. Rec. 112, 286
18. Pulliam, J. D., R. L. Seward, R. T. Henry S. A. Steinberg, 1985 : Investigating ivermectin toxicity in Collies. Vet. Med. 80, 36 40.
19. Roulet, A., O. Puel, S. Gesta, J.-F. Lepage, M. Drag, M. Soll, M. Alvinerie T. Pineau, 2003 : MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur. J. Pharmacol. 460, 85 91.
20. Sartor, L. L., S. A. Bentjen, L. Trepanier K. L. Mealey, 2004 : Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. J. Vet. Intern. Med. 18, 117 118.
21. Schinkel, A. H., 1998 : Pharmacological insights from P-glycoprotein knockout mice. Int. J. Clin. Pharmacol. Ther. 36, 9 13.
22. Seward, R. L., 1983 : Reactions in dogs given ivermectin. J. Am. Vet. Med. Assoc. 183, 493
23. ®, self-published. Dedelstorf, Germany.
24. Tranquilli, W. J., A. J. Paul R. L. Seward, 1989 : Ivermectin plasma concentrations in Collies sensitive to ivermectin-induced toxicosis. Am. J. Vet. Res. 50, 769 770.
25. Wrede, J. T. Schmidt, 2003 : OPTI-MATE Version 3.87. Ein Management-Programm zur Minimierung der Inzucht in gefährdeten Populationen. Programmbeschreibung. Institut für Tierzucht und Vererbungsforschung, Tierärztliche Hochschule Hannover.
26. Yas-Natan, E., M. Shamir, S. Kleinbart I. Aroch, 2003 : Doramectin toxicity in a collie. Vet. Rec. 153, 718 720.